Volume 3.30 | Aug 10

Prostate Cell News 3.30 August 10, 2012
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Treatment-Induced Damage to the Tumor Microenvironment Promotes Prostate Cancer Therapy Resistance through WNT16B
Researchers found that expression of the Wnt family member wingless-type MMTV integration site family member 16B (WNT16B) in the prostate tumor microenvironment attenuated the effects of cytotoxic chemotherapy in vivo, promoting tumor cell survival and disease progression. [Nat Med]
Abstract | Press Release

Register for Training Course: Air-Liquid Interface Culture of Primary Human Bronchial Epithelial Cells
PUBLICATIONS (Ranked by impact factor of the journal)


PSMA-Targeted Theranostic Nanoplex for Prostate Cancer Therapy
Investigators developed a nanoplex platform for theranostic imaging of prostate cancer (PCa). A therapeutic nanoplex containing multimodal imaging reporters was targeted to prostate-specific membrane antigen (PSMA), which is expressed on the cell surface of castrate-resistant PCa. [ACS Nano]
Abstract | Press Release

Androgen Receptor Antagonism by Divalent Ethisterone Conjugates in Castrate-Resistant Prostate Cancer Cells
Researchers illustrated that divalent ethisterone conjugates can antagonize the androgen receptor (AR) via distinct mechanisms of action, establishing new therapeutic strategies for potential applications in AR pharmacology. [ACS Chem Biol] Abstract

Comparison of mAbs Targeting Epithelial Cell Adhesion Molecule for the Detection of Prostate Cancer Lymph Node Metastases with Multimodal Contrast Agents: Quantitative Small-Animal PET/CT and Near-Infrared Fluorescence 
Scientists developed and quantitatively compared dual-labeled monoclonal antibodies (mAbs) of varying affinities against epithelial cell adhesion molecule for both noninvasive and intraoperative detection of metastatic lymph nodes in prostate cancer. [J Nucl Med] Abstract

Epigenetic-Induced Repression of MicroRNA-205 Is Associated with MED1 Activation and a Poorer Prognosis in Localized Prostate Cancer
Researchers showed that microRNA-205 targets mediator 1 (MED1) for transcriptional silencing in normal prostate cells, leading to reduction in MED1 mRNA levels, and in total and active phospho-MED1 protein. [Oncogene] Abstract

Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells
Researchers identified a novel bispecific humanized antibody that efficiently re-targets T cells to tumor cells in a strictly antigen-dependent manner and at femtomolar concentrations. [J Immunol] Abstract

Design, Synthesis and Evaluation of pH-Dependent Hydrolysable Emetine Analogs as Treatment for Prostate Cancer
The N-2′ position of the natural product emetine has been derivatived to thiourea, urea, sulfonamide, dithiocarbamate, carbamate and pH responsive hydrolysable amide analogs. In vitro studies of these analogs in PC3 and LNCaP prostate cancer cell lines showed that the analogs are generally less cytotoxic than emetine. [J Med Chem] Abstract

In Vitro and In Vivo Prostate Cancer Metastasis and Chemoresistance Can Be Modulated by Expression of Either CD44 or CD147
Scientists investigated the effects of down-regulation of CD44 or CD147 on the metastatic ability of prostate cancer cells, their docetaxel responsiveness and potential mechanisms involved in vitro and in vivo. [PLoS One] Full Article

Growth Differentiation Factor-15 Upregulates Interleukin-6 to Promote Tumorigenesis of Prostate Carcinoma PC-3 Cells
Investigators demonstrated that expression of growth differentiation factor-15 induces cell proliferation, invasion, and tumorigenesis of prostate carcinoma PC-3 cells. [J Mol Endocrinol] Abstract

Snail Transcription Factor Negatively Regulates Maspin Tumor Suppressor in Human Prostate Cancer Cells
Researchers investigated the molecular mechanisms by which Snail increases tumor motility and invasion utilizing prostate cancer cells. [BMC Cancer] Abstract | Full Article


A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer
This first-in-human, phase I, open-label study assessed safety, pharmacokinetics, and antitumor activity of TRC105 in patients with advanced refractory solid tumors. [Clin Cancer Res] Abstract

First-in-Man Application of a Novel Therapeutic Cancer Vaccine Formulation with the Capacity to Induce Multi-Functional T Cell Responses in Ovarian, Breast and Prostate Cancer Patients

This phase I clinical study examined the safety and immune activating potential of DPX-0907 in advanced stage breast, ovarian and prostate cancer patients. A total of 23 late stage cancer patients were recruited and were divided into two dose/volume cohorts in a three immunization protocol. [J Transl Med]
Abstract | Full Article | Press Release

Ready Sep Go - Watch the Video on RoboSep™, the Fully Automated Cell Separator

OncoGenex Announces Initiation of the Phase III “AFFINITY” Trial for Patients with Advanced Prostate Cancer
OncoGenex Pharmaceuticals, Inc. announced that it has initiated patient enrollment in its second Phase III clinical trial evaluating custirsen in patients with advanced prostate cancer. [OncoGenex Pharmaceuticals, Inc.] Press Release

Medivation and Astellas Announce PDUFA Action Date for Enzalutamide NDA

Medivation, Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date for the review of the investigational agent enzalutamide New Drug Application (NDA) for the potential treatment of men with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy. [Astellas Pharma Inc.] Press Release

Wellcome Trust and MRC Invest in World-Class Stem Cell Institute at Cambridge
Two of the UK’s largest funders of medical research are to invest £8 million in a new world-leading centre for stem cell biology and medicine at the University of Cambridge. The Wellcome Trust-Medical Research Council (MRC) Cambridge Stem Cell Institute will advance our understanding of stem cells and their potential to treat a range of life-threatening conditions that currently have no effective cures. [University of Cambridge] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW Epigenetics and Stem Cells 2012
October 16-17, 2012
Cambridge, United Kingdom

Visit our events page to see a complete list of events in the prostate cell community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Researcher – Transcriptomic Diagnostic for Prostate Cancer – (University of Leeds)

Postdoctoral Position – Prostate Cancer (BC Cancer Agency)

Postdoctoral Position – Prostate Cancer (Medical University of South Carolina)

Postdoctoral Position – Prostate Cancer Research (University of Texas Southwestern Medical Center)
Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Systems Biology in Prostate Cancer (Karolinska Institutet)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us